CHA₂DS₂-VA Score for Atrial Fibrillation Stroke Risk

ورودی‌های بالینی بیمار

حداقل ۱۸ — حداکثر ۱۲۰ • واحد: years

پنل نتیجه و تصمیم بالینی
در انتظار ورودی‌ها
cha2ds2 va assessment
—points
آماده برای ارزیابی

پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.

طبقات خطر و بازه‌های امتیاز:
  • Low Risk0–0
  • Moderate Risk1–1
  • High Risk2–9
Direct Clinical Answer

The CHA₂DS₂-VA Score for Atrial Fibrillation Stroke Risk calculator is designed for bedside calculating stroke risk for patients with atrial fibrillation; similar to CHA₂DS₂-VASc Score but without considering sex in clinical practice. The resulting score directly guides clinician decision-making regarding initiating guideline-directed medical therapy, antithrombotic.

Clinical Guidelines & Evidence

Calculates stroke risk for patients with atrial fibrillation; similar to CHA₂DS₂-VASc Score but without considering sex. Simplified version recommended in 2024 ESC guidelines to remove complexity of gender-based scoring.

Clinical Indication

The CHA₂DS₂-VA Score for Atrial Fibrillation Stroke Risk is indicated for bedside clinical practice to support Calculates stroke risk for patients with atrial fibrillation; similar to CHA₂DS₂-VASc Score but without considering sex. Simplified version recommended in 2024 ESC guidelines to remove complexity of gender-based scoring.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

Target Population

Target population comprises Adult patients presenting with suspected or established coronary artery disease, cardiac arrhythmias, congestive heart failure, or valvular heart defects. Clinical application is indicated across Emergency department, cardiac care unit (CCU), cardiac catheterization laboratory, and outpatient cardiology clinics.

Limitations & Contraindications

In hemodynamically unstable cardiogenic shock, cardiac arrest, or refractory acute coronary syndromes, immediate resuscitation and coronary angiography supersede scoring.

Clinical Pearls & Action Plan

Continuous 12-lead ECG monitoring, serial cardiac troponin measurements, and echocardiographic evaluation align with ESC/ACC/AHA clinical practice guidelines. Guideline pearl: Introduced in 2024 ESC guidelines to simplify CHA₂DS₂-VASc by removing sex category.

Formula & Variables:

CHA₂DS₂-VA Score = C (1) + H (1) + A₂ (age ≥75: 2) + D (1) + S₂ (2) + V (1) + A (age 65-74: 1). Range: 0-8 points.

Input Parameters

NameTypeRequiredDescription
ageintegerYesPatient age in years. <65 years (0 points), 65-74 years (1 point), ≥75 years (2 points)(years)
congestive_heart_failurestringYesCongestive heart failure or left ventricular dysfunction (1 point if present)
hypertensionstringYesHistory of hypertension or currently on antihypertensive treatment (1 point if present)
diabetes_mellitusstringYesDiabetes mellitus (1 point if present)
stroke_tia_thromboembolismstringYesPrior stroke, TIA, or arterial thromboembolism (2 points if present)
vascular_diseasestringYesVascular disease including myocardial infarction, peripheral artery disease, or aortic plaque (1 point if present)

Score Interpretation & Guidance

RangeStageDescription
0–0Low RiskVery low stroke risk
1–1Moderate RiskLow-moderate stroke risk
2–9High RiskHigh stroke risk

Evidence-Based References (EBM)

  • Lip GYH, Keshishian A, Li X, Hamilton M, Masseria C, Gupta K, Mardekian J, Friend K, Nadkarni A, Pan X, Baser O, Deitelzweig S. Effectiveness and Safety of Oral Anticoagulants Among Nonvalvular Atrial Fibrillation Patients. Stroke. 2018;49(12):2933-2944.
  • Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2021;42(5):373-498.
  • Romiti GF, Pastori D, Rivera-Caravaca JM, et al. Adherence to the 'Atrial Fibrillation Better Care' pathway in patients with atrial fibrillation: impact on clinical outcomes-a systematic review and meta-analysis of 285,000 patients. Thromb Haemost. 2022;122(3):406-414.
  • Boriani G, Ruff CT, Kuder JF, et al. Relationship between time to therapeutic anticoagulation and clinical outcomes in atrial fibrillation patients treated with warfarin. Europace. 2021;23(3):334-342.

Related calculators